In a groundbreaking study emerging from the Perelman School of Medicine at the University of Pennsylvania, researchers have unveiled compelling evidence that telemedicine visits are substantially more cost-effective compared to traditional in-person appointments. This revelation comes at a pivotal moment when healthcare systems worldwide are striving to balance quality care delivery with burgeoning financial pressures. The analysis, published in the prestigious journal JAMA Network Open, highlights that telemedicine visits for common treatable conditions incur approximately one-fifth the cost of their in-person counterparts—a staggering difference of about $400 per visit on average.
This insight directly challenges longstanding skepticism around telemedicine’s economic viability. Prior to this research, concerns persisted that telemedicine might simply function as a superficial initial contact, inevitably leading to delayed in-person visits and overall escalation in healthcare expenses. However, David Asch, MD, MBA, co-senior author and the John Morgan Professor at the University of Pennsylvania, states that their findings “suggest telemedicine can be a complete solution for many patients rather than merely a temporary band-aid.” This fresh perspective opens new avenues for healthcare systems hesitant to fully integrate telehealth services.
The rapid rise of telemedicine has been one of the most striking transformations in healthcare delivery over the past several years. The COVID-19 pandemic acted as a catalyst, spurring widespread adoption of virtual care. The University of Pennsylvania Health System (UPHS) exemplifies this shift, with telemedicine visits leaping from a mere 11,000 in 2019 to a remarkable 1 million within the span of a year, signaling a 90-fold increase. Despite normalization of many pandemic-era restrictions, telemedicine has etched itself as a permanent fixture, accounting for 4 to 6 percent of all healthcare visits across five UPHS hospitals between 2022 and 2024.
Telemedicine’s enduring popularity raises essential questions regarding its cost-effectiveness and impact on patient care continuity. The research team, spearheaded by Professor Yong Chen, PhD, sought to dissect these dynamics through rigorous data and statistical analysis. They collated billing data from over 160,000 telemedicine and in-person visits during a recent four-month window in 2024. By studying ten common billing codes—spanning respiratory symptoms, anxiety, sleep-wake disorders, neurodevelopmental challenges, and COVID-19—the researchers developed a comprehensive view of telemedicine’s financial footprint.
Crucially, the concept of “episodes” was employed to parse costs and visit frequency over time. Each episode encompassed seven days preceding an initial consultation and stretched 30 days beyond that point, enabling the team to capture not only initial visit costs but also any follow-up visits and associated expenses. This methodology allowed for a nuanced comparison that accounted for the long-term care trajectories stemming from telemedicine versus in-person care.
The results were unequivocal: the average charge for an episode initiated via telemedicine was $96, a stark contrast to the $509 linked to episodes starting with an in-person visit. This fivefold cost differential underscores telemedicine’s potential to alleviate healthcare spending without compromising immediate access to treatment. Moreover, patients who began care through telemedicine averaged just over three follow-up visits compared to over four for those seen in clinics or hospitals, indicating improved efficiency in the continuum of care.
Delving deeper into specific medical areas, the cost dynamics varied yet the overall trend favored telemedicine. In the domain of mental and behavioral health, charges per episode were comparable regardless of the visit type, likely reflecting similar treatment paradigms centered on counseling and medication management rather than diagnostic procedures. Nevertheless, telemedicine still correlated with fewer follow-up visits, suggesting enhanced care efficiency or possibly greater patient satisfaction with virtual encounters.
Conversely, respiratory symptoms presented a more pronounced divergence in cost, with telemedicine visits saving approximately $800 on average when compared to traditional appointments. Though in-person visits often involved more severe cases unsuitable for telemedicine, the researchers meticulously adjusted their analyses to ensure comparisons were made between clinically comparable patient groups. This rigorous approach strengthens the argument that cost discrepancies are primarily driven by visit modality rather than patient complexity or severity.
Beyond the immediate economic implications, the research carries broader significance for healthcare infrastructure and policy. The UPHS experience illustrates what can be achieved when telemedicine is fully integrated into clinical workflows supported by robust technological frameworks and regulatory facilitation. However, the sustainability of these gains hinges on the continuation of COVID-era regulatory flexibilities, which remain temporary and risk expiration as early as 2027. Without legislative action to preserve expanded telehealth access, the financial advantages documented may erode.
Kevin B. Mahoney, CEO of UPHS and co-author of the study, emphasizes that telemedicine’s preservation is critically linked to hospital financial health. In an era marked by tightening budgets and escalating operational costs, the approximately $400 savings per episode identified in the study could free up vital resources for reinvestment in patient care and innovative services. This financial leverage is vital for the resilience and evolution of health systems facing an increasingly complex landscape.
The study is also a testament to the versatility of telemedicine, capable of serving diverse patient populations with conditions ranging from infectious diseases to neurobehavioral disorders. As health systems look beyond the immediacy of the pandemic, these findings advocate for telemedicine to be positioned not merely as a stopgap or convenience but as an integral component of value-based care architectures.
Furthermore, the methodology adopted sets a benchmark for future comparative analyses of healthcare delivery modalities. By employing large-scale billing data and constructing episode-based financial assessments, the research provides a replicable framework to evaluate cost-efficiency and care quality across diverse clinical settings and patient demographics. This quantitative rigor adds a compelling empirical foundation to telemedicine discourse often dominated by anecdotal evidence.
As healthcare continues its digital transformation, stakeholder buy-in from policymakers, providers, payers, and patients will be crucial to sustain the momentum uncovered by this study. The evidence from UPHS serves as a clarion call for informed decision-making that balances cost containment with expanding access, aiming for equitable, effective, and efficient care delivery in the digital age.
In conclusion, the University of Pennsylvania’s recent publication elucidates a vital paradigm shift associated with telemedicine’s integration into mainstream healthcare. Not only do virtual visits offer a lower-cost alternative without increasing follow-up utilization, but they also challenge preconceived notions about telehealth’s role as a transient and less effective option. As the landscape evolves, ensuring the permanence of supportive policies and infrastructure investments will be paramount to harnessing telemedicine’s full potential as a pillar of modern healthcare systems.
Subject of Research: People
Article Title: Episode Charges and Subsequent Visits After Telemedicine vs In-Person Care
Web References:
- JAMA Network Open Article
- Journal of General Internal Medicine Study
- Penn Medicine OnDemand Service
References: 10.1001/jamanetworkopen.2025.56127
Keywords: Health care costs, Medical economics, Health care delivery
